SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. on September 22, 2004, reporting an event that occurred on September 8, 2004. The registrant is incorporated in Florida with principal executive offices in New York, New York. The filing serves as a Regulation FD disclosure regarding a presentation made by the Chief Executive Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific disclosure event rather than financial performance.
Material Changes and Disclosure Event
On September 8, 2004, Dr. V. Randy White, Chief Executive Officer, delivered a presentation in Germany. During this presentation, he disclosed that the Company possesses a peer-reviewed clinical database containing data on more than 300 patients. This information is furnished under Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies beyond the standard disclaimer regarding the non-filing status of the Item 7.01 information.
Investor Verification Checklist
- Verify the existence and peer-review status of the clinical database mentioned in the September 8, 2004 presentation.
- Confirm the specific number of patients included in the database exceeds 300.
- Review subsequent filings to determine if this clinical data has been incorporated into formal regulatory submissions or financial reports.
- Note that the company name in the metadata (Cardiff Oncology, Inc.) differs from the registrant name in the filing (Xenomics, Inc.); verify if a name change or acquisition occurred.